<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685941</url>
  </required_header>
  <id_info>
    <org_study_id>EPIC24-RAIN-FLOW</org_study_id>
    <nct_id>NCT04685941</nct_id>
  </id_info>
  <brief_title>Treatment of Slow-flow After Primary Percutaneous Coronary Intervention With Flow-mediated Hyperemia</brief_title>
  <acronym>RAIN FLOW</acronym>
  <official_title>Treatment of Slow-flow After Primary Percutaneous Coronary Intervention With Flow-mediated Hyperemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación EPIC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barcicore-Lab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación EPIC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 100 patients with ST-elevation myocardial infarction (STEMI) presenting slow-flow&#xD;
      after primary-percutaneous coronary intervention (PPCI) will be randomized to pharmacologic&#xD;
      treatment with hyperemic drugs versus flow-mediated hyperemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Slow-flow phenomena is observed around 15% of patients undergoing PPCI and has been&#xD;
      associated with poor prognosis. Hyperemic drugs, such as nitroprussiate and adenosine, have&#xD;
      not yet demonstrated to reduce the infarct size and prognosis in patients with slow flow.&#xD;
      Controlled flow-mediated hyperemia using a dedicated catheter for intracoronary saline&#xD;
      infusion has been shown to stimulate microcirculatory vasodilatation in stable patients&#xD;
      similarly as hyperemic drugs.&#xD;
&#xD;
      The aims of the study are to compare the absolute microcirculatory resistance of the&#xD;
      infarct-related artery presenting with slow flow after PPCI, as assessed by intracoronary&#xD;
      thermo-dilution, treated with standard pharmacologic hyperemia versus flow-mediated&#xD;
      hyperemia; and to compare the angiographic TIMI frame count after treatment of slow flow&#xD;
      phenomena with the two investigated strategies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 12, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic TIMI frame count</measure>
    <time_frame>2 minutes</time_frame>
    <description>Cine-fluoroscopic recording of the infarct-related artery (IRA) at 30 frames/second and off-line core-laboratory assessment of the number of cineframes needed for dye to reach standardized distal landmarks is the coprimary endpoint. Long TIMI frame counts are indicative of slow coronary flow. Previous studies showed TIMI frame counts of 30 (SD 12) after nitroprussiate in slow flow STEMI patients. The present study is powered to assess 25 percent difference between study groups (80 percent power and 5 percent alfa error).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal microcirculatory resistance (MMR)</measure>
    <time_frame>2 minutes</time_frame>
    <description>MMR is assessed by intracoronary thermodilution with a dedicated pressure wire and microcatheter (RayFlow, Hexacath) during saline infusion at 20 ml/min. MMR is measured offline by the core-laboratory at 20 seconds of the saline infusion in the standard medical treatment group and at 2 minutes and 20 seconds in the experimental group. According to previous studies, MMR was 537 Wood units (SD 289). The present study is powered to assess 30 percent difference between study groups after study intervention (80 percent power and 5 percent alfa error).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the MMR in the experimental group during the two-minutes saline infusion</measure>
    <time_frame>2 minutes</time_frame>
    <description>Experimental treatment with saline infusion via microcatheter is performed continuously recording the pressure and temperature values of the culprit artery. Off-line core-laboratory assessment of the MMR will be performed at 20 seconds and at 2 minutes of the saline infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the Absolute coronary flow between the study groups.</measure>
    <time_frame>2 minutes</time_frame>
    <description>Absolute coronary flow is performed simultaneously with the MMR. This value shows the coronary blood flow of the culprit artery during maximal hyperemia.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Microvascular Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Drug-mediated hyperemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients presenting with slow flow after PPCI undergo to at least 200 mcg of intracoronary nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flow-mediated hyperemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients presenting with slow flow after PPCI undergo to controlled saline intracoronary infusion by a dedicated microcatheter (RayFlow) at 20 ml/min during 2 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug-mediated hyperemia</intervention_name>
    <description>Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.</description>
    <arm_group_label>Drug-mediated hyperemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Flow-mediated hyperemia</intervention_name>
    <description>Intracoronary saline infusion at 20 ml/min via dedicated microcatheter (RayFlow; Hexacath, France) during two minutes.</description>
    <arm_group_label>Flow-mediated hyperemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ST elevation myocardial infarction Killip I &lt;12 hours since symptoms onset.&#xD;
&#xD;
          2. ST elevation &gt; 2 mm anterior leads or &gt; 1 mm inferior or lateral leads.&#xD;
&#xD;
          3. Sustained slow coronary flow (TIMI flow 0-2) for at least 30 seconds after stent&#xD;
             implantation or stent post-dilatation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous myocardial infarction in the culprit artery&#xD;
&#xD;
          2. Previous stroke&#xD;
&#xD;
          3. Advanced kidney disease (creatinine clearance &lt;30 ml / min).&#xD;
&#xD;
          4. Active bleeding&#xD;
&#xD;
          5. Allergy to contrast, nitroprussiate or adenosine.&#xD;
&#xD;
          6. Culprit lesion in coronary bypass, left main coronary artery or stent thrombosis&#xD;
&#xD;
          7. Macroscopic thrombus embolization in the infarct-related artery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>FUNDACION EPIC</last_name>
    <phone>+34987876135</phone>
    <phone_ext>6</phone_ext>
    <email>iepic@fundacionepic.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josep Gómez Lara, MD,PhD</last_name>
    <email>gomezjosep@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gómez Lara, PhD MD</last_name>
    </contact>
    <investigator>
      <last_name>Josep Gómez Lara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Vaquerizo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Brugaletta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alejandro Gutierrez Barrios</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Rivero</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, Mehilli J, Schömig A, Kastrati A. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv. 2010 Feb 1;3(1):27-33. doi: 10.1161/CIRCINTERVENTIONS.109.896225. Epub 2010 Jan 26.</citation>
    <PMID>20118156</PMID>
  </reference>
  <reference>
    <citation>Airoldi F, Briguori C, Cianflone D, Cosgrave J, Stankovic G, Godino C, Carlino M, Chieffo A, Montorfano M, Mussardo M, Michev I, Colombo A, Maseri A. Frequency of slow coronary flow following successful stent implantation and effect of Nitroprusside. Am J Cardiol. 2007 Apr 1;99(7):916-20. Epub 2007 Feb 12.</citation>
    <PMID>17398183</PMID>
  </reference>
  <reference>
    <citation>Wijnbergen I, van 't Veer M, Lammers J, Ubachs J, Pijls NH. Absolute coronary blood flow measurement and microvascular resistance in ST-elevation myocardial infarction in the acute and subacute phase. Cardiovasc Revasc Med. 2016 Mar;17(2):81-7. doi: 10.1016/j.carrev.2015.12.013. Epub 2016 Jan 7.</citation>
    <PMID>26905054</PMID>
  </reference>
  <reference>
    <citation>van 't Veer M, Adjedj J, Wijnbergen I, Tóth GG, Rutten MC, Barbato E, van Nunen LX, Pijls NH, De Bruyne B. Novel monorail infusion catheter for volumetric coronary blood flow measurement in humans: in vitro validation. EuroIntervention. 2016 Aug 20;12(6):701-7. doi: 10.4244/EIJV12I6A114.</citation>
    <PMID>27542781</PMID>
  </reference>
  <reference>
    <citation>Gibson CM, Schömig A. Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion. Circulation. 2004 Jun 29;109(25):3096-105. Review.</citation>
    <PMID>15226226</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Microvascular Disease</keyword>
  <keyword>Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Hyperemia</mesh_term>
    <mesh_term>Microvascular Angina</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

